Enlivex Therapeutics (ENLV) Projected to Announce Earnings on Monday

Enlivex Therapeutics (NASDAQ:ENLV) is expected to be releasing its Q1 2026 results before the market opens on Monday, August 31st. Analysts expect the company to post earnings of ($0.31) per share for the quarter. Investors may visit the the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Monday, August 31, 2026 at 4:00 PM ET.

Enlivex Therapeutics Stock Down 8.5%

Shares of NASDAQ:ENLV opened at $1.35 on Friday. Enlivex Therapeutics has a twelve month low of $1.34 and a twelve month high of $27.15. The stock’s 50 day moving average is $4.41 and its 200-day moving average is $10.45. The firm has a market capitalization of $23.61 million, a price-to-earnings ratio of -0.16 and a beta of 1.60.

Institutional Investors Weigh In On Enlivex Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Renaissance Technologies LLC lifted its position in shares of Enlivex Therapeutics by 99.4% during the 4th quarter. Renaissance Technologies LLC now owns 313,628 shares of the company’s stock worth $221,000 after buying an additional 156,336 shares in the last quarter. HRT Financial LP grew its holdings in shares of Enlivex Therapeutics by 719.4% in the fourth quarter. HRT Financial LP now owns 153,990 shares of the company’s stock valued at $108,000 after acquiring an additional 135,198 shares in the last quarter. Jane Street Group LLC increased its position in shares of Enlivex Therapeutics by 527.4% during the first quarter. Jane Street Group LLC now owns 80,759 shares of the company’s stock valued at $78,000 after acquiring an additional 67,886 shares during the last quarter. XTX Topco Ltd increased its position in shares of Enlivex Therapeutics by 44.8% during the fourth quarter. XTX Topco Ltd now owns 61,800 shares of the company’s stock valued at $43,000 after acquiring an additional 19,132 shares during the last quarter. Finally, Invesco Ltd. bought a new stake in Enlivex Therapeutics during the fourth quarter worth $43,000. Hedge funds and other institutional investors own 1.02% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on ENLV. Zacks Research upgraded shares of Enlivex Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, July 21st. Weiss Ratings restated a “sell (d)” rating on shares of Enlivex Therapeutics in a report on Friday, June 26th. Finally, Wall Street Zen raised Enlivex Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $247.50.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.